-
Je něco špatně v tomto záznamu ?
European Myeloma Network Group review and consensus statement on primary plasma cell leukemia
P. Musto, M. Engelhardt, NWCJ. van de Donk, F. Gay, E. Terpos, H. Einsele, C. Fernández de Larrea, N. Sgherza, N. Bolli, E. Katodritou, M. Gentile, B. Royer, D. Derudas, T. Jelinek, E. Zamagni, L. Rosiñol, B. Paiva, J. Caers, M. Kaiser, M....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, přehledy
- MeSH
- konsensus * MeSH
- lidé MeSH
- mnohočetný myelom terapie diagnóza patologie MeSH
- plazmocelulární leukemie * terapie diagnóza patologie MeSH
- prognóza MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Geografické názvy
- Evropa MeSH
BACKGROUND: Primary plasma cell leukemia (PPCL) is the most aggressive disorder among plasma cell malignancies, with new diagnostic criteria recently established by the International Myeloma Working Group. Studies have shown that PPCL patients receiving a combination of novel agents, but not eligible for transplantation, may have a median survival up to 2 years, extended to 3 years or more in those undergoing transplant procedures. These findings remain unsatisfactory, particularly if compared with progresses obtained in multiple myeloma. DESIGN: A European Myeloma Network (EMN) expert panel reviewed the most recent literature and selected the areas of major concern in the management of PPCL by generating and rank ordering key questions using the criterion of clinical relevance. Multistep procedures were utilized to achieve a consensus on recommendations. The Delphi questionnaire method was used and a consensus of at least 80% was reached for all final statements. RESULTS: An extended overview of current biological, clinical, prognostic, and therapeutic aspects of PPCL, including ongoing and close to start clinical trials, is presented. Furthermore, updated guidelines for the management of PPCL and practical recommendations are provided, in the context of current knowledge about this disease, also looking at possible future perspectives to ameliorate the outcome of these patients. CONCLUSIONS: PPCL still remains an unmet clinical need. Notwithstanding, some not negligible progresses have been recently achieved. The European Myeloma Network panel strongly support ongoing and planned clinical trials, as well as biological studies based on novel technologies, strategies, and treatment options that could represent breakthroughs we have been waiting for too long.
Alfred Health Monash University Melbourne Australia
Cancer Center Clínica Universidad de Navarra CIMA IDISNA CIBERONC Pamplona Spain
Department of Haematooncology University Hospital Ostrava Ostrava Czech Republic
Department of Hematology CHU de Liège Liège Belgium
Department of Hematology Erasmus MC Cancer Institute Rotterdam the Netherlands
Department of Hematology Hospital Clínic IDIBAPS University of Barcelona Barcelona Spain
Department of Hematology Theagenion Cancer Hospital Thessaloniki Greece
Department of Molecular Biotechnology and Health Sciences University of Torino Turin Italy
Department of Oncology and Onco Hematology University of Milan Milan Italy
Department of Pharmacy Health and Nutritional Science University of Calabria Rende Italy
Dipartimento di Scienze Mediche e Chirurgiche Università di Bologna Bologna Italy
European Myeloma Network Turin Italy
Faculty of Medicine University of Ostrava Ostrava Czech Republic
Hematology and Stem Cell Transplantation Unit AOU Consorziale Policlinico Bari Italy
Hematology Department Amyloidosis and Myeloma Unit Hospital Clínic IDIBAPS Barcelona Spain
Hematology Department University Hospital Hôtel Dieu Nantes France
Hematology Unit Department of Onco hematology A O of Cosenza Cosenza Italy
Hospital Clínic de Barcelona IDIBAPS University of Barcelona Barcelona Spain
Immuno Hematology Unit St Louis APHP Paris France
IRCCS Azienda Ospedaliero Universitaria di Bologna Istituto di Ematologia Seràgnoli Bologna Italy
Istinye University Ankara Liv Hospital Kavaklıdere Ankara Turkey
National and Kapodistrian University of Athens Department of Therapeutics Athens Greece
Section of Hematology Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy
The Institute of Cancer Research and The Royal Marsden Hospital London UK
University Hospital of Salamanca IBSAL CIC CIBERONC Salamanca
University Hospital Würzburg Department of Internal Medicine 2 Würzburg Germany
University of Freiburg Medical Center Faculty of Freiburg Freiburg Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25009350
- 003
- CZ-PrNML
- 005
- 20250429134505.0
- 007
- ta
- 008
- 250415s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.annonc.2025.01.022 $2 doi
- 035 __
- $a (PubMed)39924085
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Musto, P $u Department of Precision and Regenerative Medicine and Ionian Area, "Aldo Moro" University School of Medicine, Bari, Italy; Hematology and Stem Cell Transplantation Unit, AOU Consorziale Policlinico, Bari, Italy. Electronic address: pellegrino.musto@uniba.it
- 245 10
- $a European Myeloma Network Group review and consensus statement on primary plasma cell leukemia / $c P. Musto, M. Engelhardt, NWCJ. van de Donk, F. Gay, E. Terpos, H. Einsele, C. Fernández de Larrea, N. Sgherza, N. Bolli, E. Katodritou, M. Gentile, B. Royer, D. Derudas, T. Jelinek, E. Zamagni, L. Rosiñol, B. Paiva, J. Caers, M. Kaiser, M. Beksac, R. Hájek, A. Spencer, H. Ludwig, M. Cavo, J. Bladé, P. Moreau, MV. Mateos, JF. San-Miguel, MA. Dimopoulos, M. Boccadoro, P. Sonneveld
- 520 9_
- $a BACKGROUND: Primary plasma cell leukemia (PPCL) is the most aggressive disorder among plasma cell malignancies, with new diagnostic criteria recently established by the International Myeloma Working Group. Studies have shown that PPCL patients receiving a combination of novel agents, but not eligible for transplantation, may have a median survival up to 2 years, extended to 3 years or more in those undergoing transplant procedures. These findings remain unsatisfactory, particularly if compared with progresses obtained in multiple myeloma. DESIGN: A European Myeloma Network (EMN) expert panel reviewed the most recent literature and selected the areas of major concern in the management of PPCL by generating and rank ordering key questions using the criterion of clinical relevance. Multistep procedures were utilized to achieve a consensus on recommendations. The Delphi questionnaire method was used and a consensus of at least 80% was reached for all final statements. RESULTS: An extended overview of current biological, clinical, prognostic, and therapeutic aspects of PPCL, including ongoing and close to start clinical trials, is presented. Furthermore, updated guidelines for the management of PPCL and practical recommendations are provided, in the context of current knowledge about this disease, also looking at possible future perspectives to ameliorate the outcome of these patients. CONCLUSIONS: PPCL still remains an unmet clinical need. Notwithstanding, some not negligible progresses have been recently achieved. The European Myeloma Network panel strongly support ongoing and planned clinical trials, as well as biological studies based on novel technologies, strategies, and treatment options that could represent breakthroughs we have been waiting for too long.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a plazmocelulární leukemie $x terapie $x diagnóza $x patologie $7 D007952
- 650 12
- $a konsensus $7 D032921
- 650 _2
- $a mnohočetný myelom $x terapie $x diagnóza $x patologie $7 D009101
- 650 _2
- $a prognóza $7 D011379
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Engelhardt, M $u University of Freiburg Medical Center, Faculty of Freiburg, Freiburg, Germany
- 700 1_
- $a van de Donk, N W C J $u Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands
- 700 1_
- $a Gay, F $u Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino, Turin, Italy; Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy
- 700 1_
- $a Terpos, E $u Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece
- 700 1_
- $a Einsele, H $u University Hospital Würzburg, Department of Internal Medicine II, Würzburg, Germany
- 700 1_
- $a Fernández de Larrea, C $u Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain
- 700 1_
- $a Sgherza, N $u Hematology and Stem Cell Transplantation Unit, AOU Consorziale Policlinico, Bari, Italy
- 700 1_
- $a Bolli, N $u Department of Oncology and Onco-Hematology, University of Milan, Milan, Italy; Section of Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
- 700 1_
- $a Katodritou, E $u Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece
- 700 1_
- $a Gentile, M $u Hematology Unit, Department of Onco-hematology, A.O. of Cosenza, Cosenza, Italy; Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy
- 700 1_
- $a Royer, B $u Immuno-Hematology Unit, St Louis, APHP, Paris, France
- 700 1_
- $a Derudas, D $u Department of Hematology and Bone Marrow Transplant Center, Oncologic Hospital "A. Businco", Cagliari, Italy
- 700 1_
- $a Jelinek, T $u Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Zamagni, E $u IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy
- 700 1_
- $a Rosiñol, L $u Hematology Department, Amyloidosis and Myeloma Unit, Hospital Clínic, IDIBAPS, Barcelona, Spain
- 700 1_
- $a Paiva, B $u Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Universidad de Navarra, CCUN, IDISNA, CIBER-ONC CB16/12/00369, Pamplona, Spain
- 700 1_
- $a Caers, J $u Department of Hematology, CHU de Liège, Liège, Belgium
- 700 1_
- $a Kaiser, M $u The Institute of Cancer Research and The Royal Marsden Hospital, London, UK
- 700 1_
- $a Beksac, M $u Istinye University - Ankara Liv Hospital, Kavaklıdere, Ankara, Turkey
- 700 1_
- $a Hájek, R $u Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic; Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Spencer, A $u Alfred Health-Monash University, Melbourne, Australia
- 700 1_
- $a Ludwig, H $u Wilhelminen Cancer Research Institute, c/o Department of Medicine I, Center for Oncology and Hematology, Clinic Ottakring, Vienna, Austria
- 700 1_
- $a Cavo, M $u IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy
- 700 1_
- $a Bladé, J $u Department of Hematology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain
- 700 1_
- $a Moreau, P $u Hematology Department, University Hospital Hôtel-Dieu, Nantes, France
- 700 1_
- $a Mateos, M-V $u University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca
- 700 1_
- $a San-Miguel, J F $u Cancer Center, Clínica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain
- 700 1_
- $a Dimopoulos, M A $u National and Kapodistrian University of Athens, Department of Therapeutics, Athens, Greece
- 700 1_
- $a Boccadoro, M $u European Myeloma Network (EMN), Turin, Italy
- 700 1_
- $a Sonneveld, P $u Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
- 773 0_
- $w MED00000432 $t Annals of oncology $x 1569-8041 $g Roč. 36, č. 4 (2025), s. 361-374
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39924085 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429134501 $b ABA008
- 999 __
- $a ok $b bmc $g 2310996 $s 1246431
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 36 $c 4 $d 361-374 $e 20250207 $i 1569-8041 $m Annals of oncology $n Ann Oncol $x MED00000432
- LZP __
- $a Pubmed-20250415
